Cargando…
Statistical Decision Properties of Imprecise Trials Assessing Coronavirus Disease 2019 (COVID-19) Drugs
OBJECTIVES: Researchers studying treatment of coronavirus disease 2019 (COVID-19) have reported findings of randomized trials comparing standard care with care augmented by experimental drugs. Many trials have small sample sizes, so estimates of treatment effects are imprecise. Hence, clinicians may...
Autores principales: | Manski, Charles F., Tetenov, Aleksey |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
ISPOR-The Professional Society for Health Economics and Outcomes Research. Published by Elsevier Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7942186/ https://www.ncbi.nlm.nih.gov/pubmed/33933232 http://dx.doi.org/10.1016/j.jval.2020.11.019 |
Ejemplares similares
-
Coronavirus Disease 2019: Considerations for Health Technology Assessment From the National Centre for Pharmacoeconomics Review Group
por: Leahy, Joy, et al.
Publicado: (2020) -
The Role of Health Economics and Outcomes Research in Addressing Coronavirus Disease 2019 (COVID-19)
por: Mullins, C. Daniel, et al.
Publicado: (2020) -
Coronavirus Disease 2019 in 5 Neighboring Limited-Resource Countries: A Financial and Health Threat
por: Hussain, Yaseen, et al.
Publicado: (2021) -
The Economic and Public Health Imperatives Around Making Potential Coronavirus Disease–2019 Treatments Available and Affordable
por: Forsythe, Steven, et al.
Publicado: (2020) -
Using Contingent Valuation Method to Estimate Adults’ Willingness to Pay for a Future Coronavirus 2019 Vaccination
por: Vo, Nam Xuan, et al.
Publicado: (2021)